Down-regulation of tissue inhibitor of metalloproteinases-1 in gliomas: a new marker of cannabinoid antitumoral activity?

Neuropharmacology

Volumn 54, Issue 1, 2008, Pages 235-243

  Blázquez, Cristina ^a   Carracedo, Arkaitz ^a   Salazar, María ^a   Lorente, Mar ^a   Egia, Ainara ^a   González Feria, Luis ^b   Haro, Amador ^a   Velasco, Guillermo ^a   Guzmán, Manuel ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

Author keywords

Cannabinoid; Ceramide; Experimental therapeutics; Glioma; Invasion; Tissue inhibitor of metalloproteinases

Indexed keywords

1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; DRONABINOL; FUMONISIN B1; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; DRUG INHIBITION; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; TUMOR CELL; TUMOR GROWTH;

ANALYSIS OF VARIANCE; ANIMALS; CANNABINOIDS; CELL LINE, TUMOR; CELL MOVEMENT; CERAMIDES; DOWN-REGULATION; GLIOMA; HUMANS; MICE; MODELS, ANIMAL; RATS; RNA INTERFERENCE; TETRAHYDROCANNABINOL; TISSUE INHIBITOR OF METALLOPROTEINASE-1; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 37349095918     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2007.06.021     Document Type: Article

References (33)

1. Blázquez C., Casanova M.L., Planas A., Gómez del Pulgar T., Villanueva C., Fernández-Aceñero M.J., Aragonés J., Huffman J.W., Jorcano J.L., and Guzmán M. Inhibition of tumor angiogenesis by cannabinoids. FASEB Journal 17 (2003) 529-531
2. Blázquez C., González-Feria L., Álvarez L., Haro A., Casanova M.L., and Guzmán M. Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. Cancer Research 64 (2004) 5617-5623
3. Blázquez C., Carracedo A., Barrado L., Real P.J., Fernández-Luna J.L., Velasco G., Malumbres M., and Guzmán M. Cannabinoid receptors as novel targets for the treatment of melanoma. FASEB Journal 20 (2006) 2633-2635
4. Carracedo A., Gironella M., Lorente M., Garcia S., Guzmán M., Velasco G., and Iovanna J.L. Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes. Cancer Research 66 (2006) 6748-6755
5. Carracedo A., Lorente M., Egia A., Blázquez C., Garcia S., Giroux V., Malicet C., Villuendas R., Gironella M., González-Feria L., Piris M.A., Iovanna J.L., Guzmán M., and Velasco G. The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells. Cancer Cell 9 (2006) 301-312
6. Casanova M.L., Blázquez C., Martínez-Palacio J., Villanueva C., Fernández-Aceñero M.J., Huffman J.W., Jorcano J.L., and Guzmán M. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. Journal of Clinical Investigation 111 (2003) 43-50
7. Chirco R., Liu X.W., Jung K.K., and Kim H.R.C. Novel functions of TIMPs in cell signalling. Cancer Metastasis Reviews 25 (2006) 99-113
8. Deryugina E.I., and Quigley J.P. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Reviews 25 (2006) 9-34
9. Di Marzo V., and Petrocellis L.D. Plant, synthetic, and endogenous cannabinoids in medicine. Annual Review of Medicine 57 (2006) 553-574
10. Docherty A.J., Lyons A., Smith B.J., Wright E.M., Stephens P.E., Harris T.J., Murphy G., and Reynolds J.J. Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity. Nature 318 (1985) 66-69
11. Egeblad M., and Werb Z. New functions for the matrix metalloproteinases in cancer pregression. Nature Reviews Cancer 2 (2002) 161-174
12. Folgueras A.R., Pendás A.M., Sánchez L.M., and López-Otín C. Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. International Journal of Developmental Biology 48 (2004) 411-424
13. Galve-Roperh I., Sánchez C., Cortés M.L., Gómez del Pulgar T., Izquierdo M., and Guzmán M. Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nature Medicine 6 (2000) 313-319
14. Gómez del Pulgar T., Velasco G., Sánchez C., Haro A., and Guzmán M. De novo-synthesized ceramide is involved in cannabinoid-induced apoptosis. Biochemical Journal 363 (2002) 183-188
15. Grimaldi C., Pisanti S., Laezza C., Malfitano A.M., Santoro A., Vitale M., Caruso M.G., Notarnicola M., Iacuzzo I., Portella G., Di Marzo V., and Bifulco M. Anandamide inhibits adhesion and migration of breast cancer cells. Experimental Cell Research 312 (2006) 363-373
16. Guzmán M. Cannabinoids: potential anticancer agents. Nature Reviews Cancer 3 (2003) 745-755
17. 9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. British Journal of Cancer 95 (2006) 197-203
18. Hall W., Christie M., and Currow D. Cannabinoids and cancer: causation, remediation, and palliation. Lancet Oncology 6 (2005) 35-42
19. Hornebeck W., Lambert E., Petitfrère E., and Bernard P. Beneficial and detrimental influences of tissue inhibitor or metalloproteinase-1 (TIMP-1) in tumor progression. Biochimie 87 (2005) 377-383
20. Howlett A.C., Barth F., Bonner T.I., Cabral G., Casellas P., Devane W.A., Felder C.C., Herkenham M., Mackie K., Martin B.R., Mechoulam R., and Pertwee R.G. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacology Reviews 54 (2002) 161-202
21. Mackie K. Cannabinoid receptors as therapeutic targets. Annual Review of Pharmacology and Toxicology 46 (2006) 101-122
22. Ogretmen B., and Hannun Y.A. Biologically active sphingolipids in cancer pathogenesis and treatment. Nature Reviews Cancer 4 (2004) 604-616
23. Overall C.M., and Kleifeld O. Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nature Reviews Cancer 6 (2006) 227-239
24. Piomelli D. The molecular logic of endocannabinoid signalling. Nature Reviews Neuroscience 4 (2003) 873-884
25. Pisanti S., Borselli C., Oliviero O., Laezza C., Gazzerro P., and Bifulco M. Antiangiogenic activity of the endocannabinoid anandamide: correlation to its tumor-suppressor efficacy. Journal of Cell Physiology 211 (2007) 495-503
26. Portella G., Laezza C., Laccetti P., De Petrocellis L., Di Marzo V., and Bifulco M. Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis. FASEB Journal 17 (2003) 1771-1773
27. Rao J.S. Molecular mechanisms of glioma invasiveness: the role of proteases. Nature Reviews Cancer 3 (2003) 489-501
28. 2 cannabinoid receptor. Cancer Research 61 (2001) 5784-5789
29. Strongin A.Y. Mislocalization and unconventional functions of cellular MMPs in cancer. Cancer Metastasis Reviews 25 (2006) 87-98
30. Van Meter T.E., Rooprai H.K., Kibble M.M., Fillmore H.L., Broaddus W.C., and Plikington G.J. The role of matrix metalloproteinase genes in glioma invasion: co-dependent and interactive proteolysis. Journal of Neuro-Oncology 53 (2001) 213-235
31. Würtz S.O., Schrohl A.S., Moller-Sorensen N., Lademann U., Chirstensen I.J., Mouridsen H., and Brünner N. Tissue inhibitor of metalloproteinases-1 in breast cancer. Endocrine-Related Cancer 12 (2005) 215-227
32. Yamanaka M., Shegogue D., Pei H., Bu S., Bielawska A., Bielawski J., Pettus B., Hannun Y.A., Obeid L., and Trojanowska M. Sphingosine kinase 1 (SPHK1) is induced by transforming growth factor-beta and mediates TIMP-1 up-regulation. Journal of Biological Chemistry 279 (2004) 53994-54001
33. Yasui W., Oue N., Aung P.P., Matsumura S., Shutoh M., and Nakayama H. Molecular-pathological prognostic factors of gastric cancer: a review. Gastric Cancer 8 (2005) 86-94